Biocryst Pharmaceuticals reported $36.92M in Selling and Administration Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
DBV Technologies DBVT:US USD 3.05M 2.23M
Alnylam Pharmaceuticals ALNY:US USD 235.86M 65.88M
Biocryst Pharmaceuticals BCRX:US USD 36.92M 1.1M
Chugai Pharma 4519:JP JPY 22.59B 561M
Daiichi Sankyo 4568:JP JPY 113.49B 17.11B
Enanta Pharmaceuticals ENTA:US USD 12.57M 360K
Gilead Sciences GILD:US USD 1.21B 144M
GlaxoSmithKline GSK:LN GBP 1.97B 13M
Glaxosmithkline GSK:US GBP 1.97B 13M
Intra Cellular Therapies ITCI:US USD 88.38M 11.94M
IONIS PHARMACEUT IONS:US USD 34.42M 614K
Karyopharm Therapeutics KPTI:US USD 34.64M 2.69M
Mirati Therapeutics MRTX:US USD 60.8M 6.57M
Neurocrine Biosciences NBIX:US USD 186.3M 3.5M
Novavax NVAX:US USD 122.88M 14.72M
Ptc Therapeutics PTCT:US USD 80.12M 226K
Regeneron Pharmaceuticals REGN:US USD 529.1M 52.8M
Roche Holding ROG:VX 5.64B 899M
Sarepta Therapeutics SRPT:US USD 104.79M 49.53M
Ultragenyx Pharmaceutical RARE:US USD 69.84M 1.7M
Vertex Pharmaceuticals VRTX:US USD 246.8M 31.5M
YTE INCY:US USD 266.46M 13.18M